Principal Financial Group Inc. Boosts Stock Holdings in Pediatrix Medical Group, Inc. (NYSE:MD)

Principal Financial Group Inc. boosted its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 14.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 513,618 shares of the company’s stock after purchasing an additional 63,581 shares during the quarter. Principal Financial Group Inc. owned about 0.60% of Pediatrix Medical Group worth $5,953,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Franklin Resources Inc. bought a new position in shares of Pediatrix Medical Group during the 3rd quarter valued at approximately $598,000. Barclays PLC lifted its position in Pediatrix Medical Group by 302.9% during the third quarter. Barclays PLC now owns 142,087 shares of the company’s stock valued at $1,646,000 after purchasing an additional 106,817 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Pediatrix Medical Group by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company’s stock worth $22,452,000 after buying an additional 45,155 shares in the last quarter. M&T Bank Corp increased its holdings in shares of Pediatrix Medical Group by 20.1% in the 3rd quarter. M&T Bank Corp now owns 85,264 shares of the company’s stock worth $988,000 after buying an additional 14,247 shares during the last quarter. Finally, Jane Street Group LLC raised its position in shares of Pediatrix Medical Group by 54.0% during the 3rd quarter. Jane Street Group LLC now owns 303,283 shares of the company’s stock valued at $3,515,000 after buying an additional 106,332 shares in the last quarter. Institutional investors own 97.71% of the company’s stock.

Insider Buying and Selling at Pediatrix Medical Group

In related news, EVP Mary Ann E. Moore sold 8,108 shares of Pediatrix Medical Group stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the sale, the director now owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by corporate insiders.

Pediatrix Medical Group Trading Down 0.7 %

NYSE MD opened at $13.12 on Thursday. The stock has a market cap of $1.13 billion, a PE ratio of -4.29, a PEG ratio of 2.00 and a beta of 1.57. Pediatrix Medical Group, Inc. has a 12 month low of $6.62 and a 12 month high of $16.41. The company’s 50-day moving average price is $14.33 and its 200-day moving average price is $11.35. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.29 EPS. Equities research analysts forecast that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on MD shares. Truist Financial lifted their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Jefferies Financial Group boosted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. UBS Group raised their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Finally, Macquarie began coverage on shares of Pediatrix Medical Group in a report on Monday, December 16th. They issued an “outperform” rating and a $18.00 target price for the company. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $16.42.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.